Investigating the Expression and Function of the Glucose Transporter GLUT6 in Obesity.
Sing-Young ChenEllen M OlzomerMartina BerettaJames CantleyCraig S NunemakerKyle Lee HoehnFrances L ByrnePublished in: International journal of molecular sciences (2022)
Obesity-related insulin resistance is a highly prevalent and growing health concern, which places stress on the pancreatic islets of Langerhans by increasing insulin secretion to lower blood glucose levels. The glucose transporters GLUT1 and GLUT3 play a key role in glucose-stimulated insulin secretion in human islets, while GLUT2 is the key isoform in rodent islets. However, it is unclear whether other glucose transporters also contribute to insulin secretion by pancreatic islets. Herein, we show that SLC2A6 ( GLUT6 ) is markedly upregulated in pancreatic islets from genetically obese leptin-mutant ( ob/ob ) and leptin receptor-mutant ( db/db ) mice, compared to lean controls. Furthermore, we observe that islet SLC2A6 expression positively correlates with body mass index in human patients with type 2 diabetes. To investigate whether GLUT6 plays a functional role in islets, we crossed GLUT6 knockout mice with C57BL/6 ob/ob mice. Pancreatic islets isolated from ob/ob mice lacking GLUT6 secreted more insulin in response to high-dose glucose, compared to ob/ob mice that were wild type for GLUT6 . The loss of GLUT6 in ob/ob mice had no adverse impact on body mass, body composition, or glucose tolerance at a whole-body level. This study demonstrates that GLUT6 plays a role in pancreatic islet insulin secretion in vitro but is not a dominant glucose transporter that alters whole-body metabolic physiology in ob/ob mice.
Keyphrases
- high fat diet induced
- blood glucose
- wild type
- insulin resistance
- body composition
- type diabetes
- metabolic syndrome
- high dose
- body mass index
- glycemic control
- endothelial cells
- weight loss
- poor prognosis
- public health
- healthcare
- bone mineral density
- skeletal muscle
- emergency department
- blood pressure
- low dose
- induced pluripotent stem cells
- risk assessment
- stress induced
- polycystic ovary syndrome
- human health
- adverse drug